OSCR · Oscar Health, Inc. · Stock research

Current Thesis

The binary the prior note was waiting on has been graded. Oscar reported Q2 before the open on August 6 2026: EPS $1.10 against a $0.49 consensus, revenue $4,880.2M against $4,751M expected, earnings from operations $388.6M versus a $230.5M operating loss in Q2 2025, and full-year earnings-from-operations guidance raised by $250M to $500–700M. The stock closed $26.54 that session against $30.11 on August 5, then recovered to $27.90 on August 7 (+5.12%). The $28 weekly line the prior note named as the thesis-break level gave way on that Friday close.

What the market repriced was not the quarter but the shape of the rest of the year. First-half earnings from operations of $1,092.7M sit above the entire raised full-year band; CFO Scott Blackley told the call that membership churn previously framed at 1–2% is now expected at roughly twice that in the back half, tied to CMS program-integrity eligibility and data-matching processes that slipped out of Q2. Effectuated membership was 2,963,002 at June 30, against 3.17M reported at March 31.

The leg an investor would now be buying is a post-print reset — proven underwriting margin, a raised guide, four sell-side target increases in two sessions — held against a second half management has told the market will be worse and a subsidy decision that is not on the calendar. Theme reads SATURATED, dated August 6 2026: a beat of more than twice consensus EPS plus a $250M guidance raise produced a double-digit down session, and the target raises arrived after the repricing rather than ahead of it.

Bullish and bearish views on Oscar Health, Inc.

The model's bull view on Oscar Health, Inc. (OSCR), in brief: The margin recovery is now reported for two consecutive quarters, not modelled. The bear view: The raised full-year band is below the half-year result. Both cases follow in full.

Bull Case

• The margin recovery is now reported for two consecutive quarters, not modelled. Q2 2026 MLR 79.2% against 91.1% in Q2 2025; H1 MLR 75.0%; H1 net income $1,040.8M on revenue $9,527.4M (results release, 2026-08-06).
• Guidance moved up on three of four lines. Full-year MLR cut to 81.5–82.5% from 82.4–83.4% (90bp better at the midpoint), SG&A ratio to 15.6–16.1% from 15.8–16.3%, earnings from operations to $500–700M from $250–450M, revenue reaffirmed at $18.7–19.0B.
• Cost control ran ahead of the guide. Q2 SG&A expense ratio 14.2%, H1 14.7%, against a full-year band of 15.6–16.1%.
• The sell-side board moved up hard after the print. Barclays $35 → $39 (Andrew Mok, Overweight, 2026-08-07), Baird $19 → $27, UBS $20 → $26 (Neutral), Bank of America $13 → $25. Mean target $28.20 from $25.20 on August 4; the low target rose to $19 from $13.
• Membership growth is still the largest in the group. 2,963,002 effectuated members at June 30, +46% year over year, while Molina reported 283,000 marketplace members against 655,000 at end-2025 (Molina Q2, 2026-07-22).
• 2027 pricing is being filed up across the industry. KFF's July 8 2026 review of preliminary filings found a median 14% proposed increase across 77 carriers in 16 states and DC, 20 of them above 20%.
• A second dated re-rating event is already scheduled. Investor Day September 16 2026, 9:00 AM ET, where long-term targets and the first 2027 framework get set (announced 2026-07-28).

Bear Case

• The raised full-year band is below the half-year result. Earnings from operations $1,092.7M for H1 against a $500–700M full-year guide; consensus full-year EPS stands at $1.55 while Q1 diluted EPS was $2.07 and Q2 $1.10.
• Quality of the beat. Q2 included $164M of favorable prior-period reserve development — earnings sourced from prior-year claims experience rather than current-period underwriting.
• Churn guidance doubled inside one call. Blackley put back-half membership lapse at roughly twice the previously communicated 1–2%, attributed to CMS eligibility and data-matching processes; management framed it as timing and left revenue guidance unchanged, which puts the burden of proof on the Q3 membership count.
• Price is now below the average target it spent July above. August 7 close $27.90 against a $28.20 mean and a $26.50 median, with the board still 3 Buy / 7 Hold / 1 Sell across 11 analysts.
• The subsidy option remains unpriced and unscheduled. Enhanced premium tax credits lapsed December 31 2025; the House-passed three-year extension (230–196, January 8 2026) has not cleared the Senate, where S. 3385 failed to reach 60 votes.
• Insider supply preceded the break. CEO Mark Bertolini sold 1,238,996 Class A shares June 29–30 2026 at weighted averages of $27.78–$30.61 under a 10b5-1 letter dated November 10 2025 (amended March 24 2026), cutting his direct holding to 7,751,570 from 8,990,566 (Form 4 filed 2026-07-01).
• The sector has been punishing good prints. Elevance beat Q2 on July 15 2026 and its conservative guidance raise sold managed care off broadly; Oscar's own August 6 session repeated the pattern.

Setup & Price Structure

The post-print sequence is the structure: $30.11 close August 5, $26.54 close August 6, $27.90 close August 7 on a 5.12% bounce. That August 7 weekly close sits under every July close (the lowest was $28.19 on July 24), under the 50-day moving average measured at $28.26 on August 4, and 30 cents under the current $28.20 mean target. The 52-week range is $10.69 to $33.10; the run's ceiling remains the $33.10 high and the $31.94 intraday print of July 29.

Crowding and positioning observables, stated as observables:

• Four price-target raises landed inside two sessions on August 7–8 (Barclays, UBS, Baird, Bank of America) — after the August 6 gap-down, not before it. The rating mix did not change: 3 Buy / 7 Hold / 1 Sell.
• Short interest stood at 19.58M shares, 7.86% of a 249.19M float, 3.33 days to cover at the most recent FINRA settlement, up from 17.47M a month earlier. The next report covering the mid-August settlement date is the first post-print positioning update.
• Participation had already been contracting into the print: four consecutive below-average volume sessions through August 4, against a twenty-day average that itself decayed from 4.15M to 4.01M shares.
• Insider direction was one-way in the last week of June (see Form 4 above); a co-founder trust converted Class B to Class A and sold on July 1 2026.
• Consensus forward estimates now sit at $18.57B revenue and $1.55 EPS for FY2026, and $20.00B and $1.70 for FY2027 — a 7.72% revenue growth step-down from 2026's 58.69%.

The base has not re-formed. One up-session off a gap-down close is a single observation, and the August 6 low close of $26.54 is the reference the tape has not yet retested.

Catalyst Calendar (next 30 days)

• 2026-08-14 — Q2 2026 13F filing deadline. First institutional read on whether the holder base broadened through the June–July re-rate or thinned into the August 6 break.
• ~2026-08-26 (est.) — FINRA short-interest report for the mid-August settlement date. Shows whether the 19.58M-share base grew into the gap-down or covered on it.
• ~2026-08-31 (est.) — State regulators continue finalizing 2027 ACA rates against the 14% median proposed in the July filings. The gap between filed and approved sets 2027 revenue per member.
• Beyond the 30-day window but dated: 2026-09-16 Investor Day, 9:00 AM ET (long-term targets, first 2027 framework); ~2026-09-30 federal appropriations deadline, the next plausible vehicle for an enhanced-premium-tax-credit extension; ~2026-11-01 (est.) 2027 open enrollment opens; ~2026-11-05 (est.) Q3 2026 print, the first hard check on back-half churn and the $500–700M band.

What Would Change Our Mind

The August 6 gap-down is the structure that now governs. Treating it as a reset requires the $26.54 reaction close to hold on any retest; a weekly close below $26.50 loses that close and the $26.50 median analyst target together, and would read the session as distribution rather than repricing. Secondary conditions that would break the leg independent of price: the ~September 30 appropriations vehicle passing with no enhanced premium tax credit extension attached and no reconciliation vehicle named, which retires the subsidy option entirely; or a Q3 membership count that lands materially below 2,963,002 with revenue guidance cut, which would recast the "timing" framing of the churn as a permanent base reduction.

What would rebuild the case: a September 16 Investor Day that guides 2027 marketplace membership and premium up rather than down, against Molina having stripped roughly $1B of marketplace premium out of its own 2027 plan (2026-07-22); or a Q3 MLR inside the new 81.5–82.5% band without reliance on prior-period development.

Correlation Notes

• Oscar trades as the highest-beta expression of ACA marketplace policy. It carries no Medicaid or Medicare Advantage book, so peer results only rationally transfer through the exchange segment: Centene's 79.2% Q2 health benefits ratio and its FY2026 adjusted-EPS raise to more than $4.80 from more than $3.40 (2026-07-28) was a positive exchange read; Molina's cut to a $0.75/share full-year marketplace loss (2026-07-22) was the opposite.
• Group-level risk appetite dominates on some days regardless of company news — the July 15 2026 Elevance print sold the whole managed-care complex down on a beat.
• Policy headlines (premium tax credits, CMS program-integrity rules) move the stock independent of operating results, and those headlines are unscheduled between now and the ~September 30 appropriations deadline.
• The name's five-year beta has run above 2, so index-level drawdowns are amplified into a float of roughly 249M shares against 308.32M shares outstanding.